Confo – Drug discovery platform for high value GPCR targets

Despite accounting for quarter of the global market share of therapeutic drugs, GPCRs still remain a large untapped opportunity as many receptors remain unexplored or are undruggable. Confo aims to unleash the therapeutic potential of GPCRs, and the company has developed a proprietary technology that uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, thereby allowing fragment-based drug discovery to identify first-in-class GPCR modulators for treating patients with severe and underserved diseases, with a current emphasis on rare diseases.